What follows is how the picture tends to shift through the 30s and 40s, what the menopausal transition does and does not alter, which markers are worth following over time, and when the change in your symptoms is worth raising with a clinician.
PCOS, short for polycystic ovary syndrome, is a hormonal and metabolic condition in which ovulation is irregular or absent, androgen activity tends to run higher than expected, and the ovaries can hold an unusually large number of small, paused follicles.
A 2003 international consensus set out criteria that are still widely used, requiring two of those three features to be present once other causes of the same picture have been excluded 1. That structure matters for the question on this page, because a person can stop meeting two of three criteria while the biology that produced them is still running.
Underneath the criteria sits a self-reinforcing loop. When cells respond less efficiently to insulin, the pancreas releases more of it, and higher circulating insulin nudges the ovaries toward producing more androgens while lowering the carrier protein that normally keeps androgens bound and inactive. More free androgen activity interferes with the orderly maturation and release of one follicle per month, which is why cycles stretch out or skip altogether. Research suggests that insulin resistance sits at the centre of the long-term metabolic consequences seen in PCOS 2.
The name is also a poor description of the thing. The 'cysts' are ordinary follicles that stalled partway through development rather than growths, and plenty of people who meet the criteria have ovaries that look unremarkable on a scan. PCOS is better understood as a pattern spread across reproductive, metabolic and skin-related systems, which is part of why it does not behave like an illness with a clean start and a clean finish.
Not in the sense of vanishing. PCOS is generally regarded as a long-term condition, and while its visible features can quieten for years at a stretch, the underlying tendency in how the ovaries respond to hormonal signals and how the body handles insulin tends to stay put. Research suggests that PCOS affects psychological, reproductive and metabolic health across the whole lifespan rather than during one phase of it 3.
What genuinely can change is whether a person still meets the diagnostic criteria on any given day. Someone diagnosed at 22 with long cycles and persistent acne may be ovulating predictably at 38 with settled skin. On paper, two of three criteria are no longer satisfied. In practice the metabolic side of the picture has not been retired, and the same person can watch features return after a period of weight gain, broken sleep or sustained stress.
This distinction does most of the work on this page. Symptom remission is real, it is meaningful, and it is worth having. It is not the same as the condition ending, and it does not remove the reason for periodic checks of blood sugar, blood pressure and lipids.
It is also worth naming what nobody can promise. There is no intervention that removes the underlying tendency permanently, and anyone claiming otherwise is overselling. What is realistic is a long stretch of quiet symptoms alongside steady attention to the markers that drift silently.
Because the reproductive features are the most age-sensitive part of PCOS. Androgen production from the ovaries declines gradually through the 30s and 40s, and the pool of small follicles shrinks with age in everyone. In people with PCOS, who often start with a larger follicle pool and a higher androgen output, that ordinary decline can pull cycle length back toward typical and soften skin and hair changes. Research suggests that the reproductive features of PCOS become less pronounced with age while the metabolic implications continue into later life 4.
The second driver is metabolic. Anything that improves how efficiently cells respond to insulin tends to loosen the loop described earlier, which can allow ovulation to resume and androgen-driven symptoms to settle. The reverse is equally true, which is why many people describe their PCOS as coming and going in waves that track with life circumstances rather than following a straight line.
The third driver is simply measurement. Two of the three diagnostic criteria rely on having cycles to observe and ovaries actively recruiting follicles. As both change with age, the criteria stop describing the person well, even though nothing about their metabolic biology has reversed. Fading symptoms are a change in how the condition is expressed, not a sign that it has resolved.
The reproductive features usually peak early and ease later, while the metabolic features tend to build quietly in the background, so the questions worth asking change by decade.
| Life stage | What often changes | What stays worth watching |
|---|---|---|
| Teens and early 20s | Cycles are irregular from the start, skin and hair changes are often at their most noticeable | Early signs of insulin resistance, weight pattern, mood |
| Mid 20s to mid 30s | Cycle irregularity and androgen-related symptoms are usually most active | Fasting glucose, HbA1c, lipids, blood pressure |
| Late 30s to mid 40s | Cycles often become more regular, skin and hair symptoms frequently soften | Blood sugar markers, waist measurement, liver enzymes |
| Menopausal transition | Cycles become erratic for everyone, so cycle-based criteria stop distinguishing anything | Androgen markers, blood pressure, glucose, lipid shifts |
| After menopause | The reproductive questions close entirely | Cardiometabolic markers and long-term follow-up |
This table describes general patterns, not a forecast for any one person. Plenty of people move through these stages with a milder version of the pattern, and a few find their symptoms barely shift at all.
It depends which part of PCOS you mean, and the two halves move in opposite directions. The reproductive and skin-related features typically become less prominent over time, while metabolic and cardiovascular considerations tend to accumulate, which is the reverse of what most people expect when they ask the question. Research suggests that PCOS needs long-term management precisely because its health implications extend well beyond the reproductive years 5.
The metabolic drift is rarely dramatic. Blood pressure edges up, fasting glucose creeps, triglycerides rise a little, body composition shifts toward the midsection, and none of it announces itself. Studies indicate that type 2 diabetes, metabolic syndrome and fatty change in the liver appear more often in PCOS than in comparable groups without it 2.
Age adds its own layer on top. Insulin sensitivity tends to decline with age in the general population, muscle mass falls if nothing counters it, and the protective hormonal environment of the reproductive years changes around menopause. In people with PCOS these ordinary age-related shifts land on a baseline that was already tilted.
So 'worse' is the wrong frame. 'Different' is closer. The symptoms that drove the original diagnosis often become the quietest part of the picture, while the part nobody feels becomes the part most worth measuring. That is the practical argument for regular bloodwork rather than symptom-led check-ins.
Usually not as a brand new condition. PCOS is generally understood to take shape around puberty, when the hormonal signalling that governs ovulation first comes online, so a diagnosis arriving in the mid 30s or 40s is most often recognition of a pattern that has been present for years rather than a new onset.
There are several reasons the recognition arrives late. Symptoms can be mild enough to pass as ordinary variation. Cycles may have looked regular for long stretches. Years spent on cycle-regulating care can mask the underlying pattern until it is stopped. And the metabolic shifts of the 30s can push a quiet tendency over the threshold where symptoms become obvious, which feels like new onset from the inside even when the biology is long-standing.
What deserves separate handling is a fast-moving change. Signs of excess androgen activity that appear quickly in later life, rather than gradually, are worth discussing with a clinician promptly, because several other hormonal conditions can produce a similar picture and the diagnostic criteria require those alternatives to be excluded before PCOS is the label that fits 1. The speed of change carries information that a single lab value does not.
No. Menopause removes the cycle from the equation for everyone, so irregular periods stop being a way to distinguish who has PCOS and who does not, but the hormonal and metabolic differences do not end with the final period. A systematic review and meta-analysis of PCOS through the menopausal transition and beyond suggests that androgen levels remain higher in women with PCOS than in comparison groups into the postmenopausal years 6.
The physiology behind that is reasonably intuitive. After menopause, ovarian oestrogen output falls sharply in everyone, while androgen production from the ovaries and adrenal glands declines more slowly. The balance between the two shifts in a more androgen-weighted direction for most women, and a person who started from a higher androgen baseline carries that difference forward.
The practical consequence is that the conversation changes rather than ends. Cycle regularity, ovulation and follicle counts stop being relevant questions. Blood pressure, glucose handling, lipid pattern, body composition and the general cardiometabolic picture take their place. Research suggests that the health implications of PCOS continue after menopause and warrant ongoing attention to cardiometabolic health in later life 4.
Many women are told, or assume, that menopause draws a line under the whole thing. It draws a line under one chapter. The rest of the history still belongs in the record, and it still shapes which markers are worth following.
Cardiometabolic health is the part of the picture that matters most over decades. A systematic review and meta-analysis found that PCOS is associated with a higher long-term likelihood of type 2 diabetes, high blood pressure and metabolic syndrome, while findings on cardiovascular events specifically were less consistent across studies 7.
The mechanism follows from the insulin loop. When cells respond less efficiently to insulin over many years, the knock-on effects show up in fasting glucose and HbA1c, in triglycerides and HDL, in blood pressure, and in where the body stores fat. Each of these is measurable long before anything is felt, which is exactly why they are tracked rather than waited for.
Menopause then changes the hormonal backdrop against which all of this plays out. Research suggests that cardiovascular risk factors deserve particular attention in aging women with PCOS as they move through and beyond the menopausal transition 8.
Two caveats keep this honest. First, these are group-level patterns, and a group pattern is not a personal forecast. Plenty of people with PCOS reach their 70s with unremarkable metabolic bloodwork. Second, a single value outside a reference range is an observation, not a conclusion. It may reflect the underlying pattern, or recent illness, or the circumstances of the draw. What it earns is a conversation and a repeat measurement, not a verdict.
Because the part that is easiest to feel is not the part that matters most over time. Research suggests that PCOS needs long-term management because its consequences stretch across decades rather than resolving with the reproductive years 5.
There is also a dimension that bloodwork does not capture directly. Research suggests that PCOS carries psychological effects alongside its reproductive and metabolic manifestations across the lifespan 3. People who were told as teenagers that their condition would sort itself out often arrive in their 40s having had no structured follow-up at all, which is a documentation problem as much as a medical one.
Continuity is the underrated asset here. A single reading tells you where a marker sits. Five readings across five years tell you which direction it is travelling and how fast, and direction is usually the more actionable fact. A fasting glucose that has climbed steadily while staying inside the standard range says something a one-off result cannot.
That is the argument for keeping the history attached to you rather than scattered across clinics. Whoever reviews your results in a decade will want the earlier numbers, not just the current ones.
Total testosterone measures the main androgen circulating in the blood, and it is one of the values clinicians look at when assessing signs of excess androgen activity, alongside symptoms and other hormones. The Testosterone Total guide covers the test itself in depth.
Typical lab reference ranges for women run roughly 8 to 120 ng/dL, and FitScript's optimal range for women is 15 to 70 ng/dL. Reference ranges vary by lab, age and sex, and optimal ranges are optimization targets rather than diagnostic cut-offs.
One value on its own defines nothing. It is read together with cycle history, symptoms and related markers, and a result outside the standard range is worth discussing with a clinician rather than interpreting alone.
The markers that matter most over the long run are metabolic rather than reproductive, which is why a sensible panel looks wider than hormones.
| Marker | What it reflects | Why it comes up here |
|---|---|---|
| Fasting glucose and HbA1c | Current and longer-term blood sugar handling | The core of metabolic follow-up over years |
| Fasting insulin | How hard the pancreas is working to hold glucose steady | The insulin side of the loop, often moves first |
| SHBG | The carrier protein that binds androgens in the blood | Lower values leave more androgen biologically active |
| Lipid panel, including triglycerides and HDL | How fats are transported and cleared | Shifts alongside insulin sensitivity |
| LH and FSH | Pituitary signals that drive the cycle | Context for cycle pattern before menopause |
| AMH | The size of the remaining follicle pool | Read alongside the ovarian picture, falls with age |
| TSH and prolactin | Thyroid and pituitary signalling | Part of excluding other causes of the same symptoms |
| Liver enzymes such as ALT | Liver stress | Fatty change in the liver tracks with insulin resistance |
Research suggests that insulin resistance and its downstream metabolic consequences are central to long-term health in PCOS, which is the reason these markers are followed repeatedly rather than checked once 2. Blood pressure and waist measurement are not blood tests, but they belong in the same review.
FitScript's membership is built around repeat testing, with 150+ biomarkers tested per year and interpretation by Atlas, its AI health advisor.
A lot shifts how the picture looks month to month, and nothing yet removes the underlying tendency.
On the biology side, body composition and insulin sensitivity are the main levers, which is why symptoms so often track with periods of weight change, illness recovery, disrupted sleep or sustained stress. Research suggests that weight and insulin resistance shape the metabolic course of PCOS over time 2. Age shifts the picture independently, as described earlier. Some medicines also influence hormone and metabolic results, so ask your prescriber how anything you take may read on a panel.
On the measurement side, several ordinary things move a result without anything changing in your health. Where you are in your cycle when blood is drawn matters for several hormones. Androgens are generally measured in the morning, because levels drift through the day. Fasting status affects glucose, insulin and triglycerides. A hard training session in the previous day or two can nudge several values. Different labs use different assays and different reference ranges, so comparing a number from one lab directly against a range from another is a common source of confusion.
None of this is advice about what to do next. Treatment decisions belong to a licensed provider who can see your full history, your current results and your symptoms together.
By pattern, not by any single test. There is no one blood value that confirms or excludes PCOS, which surprises most people. Assessment combines cycle history, a clinical or biochemical picture of androgen activity, an ovarian ultrasound where relevant, and exclusion of other conditions that produce overlapping signs 1.
After menopause the assessment has to work differently, because two of the three criteria depend on having cycles and actively recruiting follicles.
The useful way to read your own results is in three steps. The observation is the value itself and where it sits against the reference range. The meaning is what that value may reflect, which is almost always more than one possibility. The next step is the conversation, where a clinician weighs the result against your symptoms, your history and your other markers.
Testing shows where your biology sits today and the direction it is moving over repeat draws. That is genuinely valuable. What it does not do is hand you a diagnosis on its own.
In practice it describes quiet symptoms rather than a condition that has ended. When clinicians describe someone's PCOS as well controlled, they generally mean cycles have become predictable, androgen-related symptoms have settled, and metabolic markers sit in a reassuring place. All three can be true at once while the underlying tendency remains.
That matters for two practical reasons. The first is that features can return. A long quiet stretch does not immunise anyone against a return of symptoms after a significant change in weight, sleep, stress or general health. The second is that the metabolic follow-up does not stop just because the reproductive symptoms did, which is the most common gap in long-term care for this condition.
It also helps to drop the expectation of a finish line. PCOS is better managed as a long-term relationship with your own data than as a problem to be closed out. People who keep a steady thread of results over the years tend to catch drift early, when the options are widest and the conversation with a clinician is most useful.
Any time the pattern changes in a way you did not expect, and on a regular schedule even when it does not. Specific prompts include the following.
Never ignore a result that falls outside the standard range, and never let a single value convince you of a diagnosis either. Both errors are common and both are avoidable. Discuss your results and any treatment decisions with a clinician or licensed provider who can see the whole picture. This article is educational and is not medical advice.
If you want to go deeper on the day-to-day picture, see the guide to pcos symptoms, the background on what causes pcos, and the detailed breakdown of pcos insulin resistance.
No, it is not described as something that disappears. Symptoms can quieten for long stretches, and a person may stop meeting the diagnostic criteria, but the underlying hormonal and metabolic tendency generally remains. That is why follow-up continues even during the quiet years.
Regular cycles are a genuinely good sign, and they often arrive naturally through the late 30s and 40s. They do not by themselves mean the condition has ended, because the metabolic side of the picture is not measured by cycle length. Your clinician can tell you what the full set of current markers suggests.
Yes, that is a common experience. Features often track with changes in weight, sleep, stress and general health, so a long quiet period can be followed by a return of irregular cycles or skin and hair changes. If symptoms return, it is worth booking a review rather than waiting to see.
A new diagnosis in your 40s usually means a long-standing pattern has finally been identified, rather than a condition starting from scratch. The pattern typically takes shape around puberty and can go unrecognised for years. Symptoms that appear suddenly in later life are a separate situation and should be assessed by a clinician promptly, because other causes can look similar.
Menopause ends the cycle-based part of the question, because periods stop for everyone. The hormonal and metabolic differences do not end at the same time. After menopause the focus of follow-up shifts toward blood pressure, blood sugar, lipids and body composition.
Not in the way most people mean. The reproductive and skin-related symptoms often become less prominent over time, while metabolic markers can drift quietly in the background. That is the main reason regular bloodwork is more useful than relying on how you feel.
Clinicians commonly follow fasting glucose, HbA1c, fasting insulin, a lipid panel, liver enzymes, SHBG and androgen markers, alongside blood pressure and waist measurement. No single test confirms or excludes the condition. The value comes from repeating the same markers over time so the direction of travel is visible.
Treat it as an observation rather than a conclusion, and take it to a clinician. A single value can be affected by the timing of the draw, fasting status, recent illness or recent hard training, so it is usually repeated before anything is decided. A licensed provider decides on any next step.